← Issue №1/ week of Jun 24, 2026/Endoscopy

Adverse events associated with endoscopic retrograde cholangiopancreatography (ERCP) and ERCP-related procedures.

From GI Signals issue №1: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy guideline · Jun 30, 2026 · GIE · IF 8.0

Adverse events associated with endoscopic retrograde cholangiopancreatography (ERCP) and ERCP-related procedures.

Guideline / reviewERCPguideline
Clinical takeawayApply ASGE ERCP adverse-event guidance now: routine rectal NSAID (indomethacin or diclofenac 100 mg) for post-ERCP pancreatitis prophylaxis and prophylactic pancreatic-duct stenting in high-risk cases, plus aggressive periprocedural hydration.
What it foundThe abstract does not provide specific quantitative results on adverse event rates or comparisons.
ContextThis appears to be a guideline publication aiming to summarize or update standards on ERCP-related adverse events, but without the abstract providing details, it cannot be placed against prior evidence.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

ASGE Standards of Practice Committee … Thosani NC · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
← Read the whole of issue №1 Every paper GI Signals surfaces gets a page like this one. All issues